Coralie Amadou1, Géraldine Bera2,3, Malek Ezziane4, Linda Chami3,4, Thierry Delbot2, Agnès Rouxel2, Monique Leban5, Genevieve Herve6, Fabrice Menegaux7, Laurence Leenhardt1,3, Aurélie Kas2,3, Christophe Trésallet7,8, Cécile Ghander1, Charlotte Lussey-Lepoutre9,10. 1. Department of Thyroid and Endocrine Tumours, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 2. Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 3. Laboratoire d'imagerie biomedicale (LIB), INSERM U1146, Sorbonne University, Paris, France. 4. Department of Radiology, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 5. Laboratory of Endocrine Biochemistry, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 6. Department of Histopathology, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 7. Department of Endocrine Surgery, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. 8. Laboratoire d'imagerie fonctionnelle (LIF), INSERM U678, Sorbonne University, Paris, France. 9. Department of Nuclear Medicine, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. charlotte.lussey@inserm.fr. 10. INSERM, UMR970, Paris-Cardiovascular Research Center, 75015, Paris, France. charlotte.lussey@inserm.fr.
Abstract
BACKGROUND: To evaluate FCH-PET/CT and parathyroid 4D-CT so as to guide surgery in patients with primary hyperparathyroidism (pHPT) and prior neck surgery. METHODS: Medical records of all patients referred for a FCH-PET/CT in our institution were systematically reviewed. Only patients with pHPT, a history of neck surgery (for pHPT or another reason) and an indication of reoperation were included. All patients had parathyroid ultrasound (US) and Tc-99m-sestaMIBI scintigraphy, and furthermore, some patients had 4D-CT. Gold standard was defined by pathological findings and/or US-guided fine-needle aspiration with PTH level measurement in the washing liquid. RESULTS: Twenty-nine patients were included in this retrospective study. FCH-PET/CT identified 34 abnormal foci including 19 ectopic localizations. 4D-CT, performed in 20 patients, detected 11 abnormal glands at first reading and 6 more under FCH-PET/CT guidance. US and Tc-99m-sestaMIBI found concordant foci in 8/29 patients. Gold standard was obtained for 32 abnormal FCH-PET/CT foci in 27 patients. On a per-lesion analysis, sensitivity, specificity, positive and negative predictive values were, respectively, 96%, 13%, 77% and 50% for FCH-PET/CT, 75%, 40%, 80% and 33% for 4D-CT. On a per-patient analysis, sensitivity was 85% for FCH-PET/CT and 63% for 4D-CT. FCH-PET/CT results made it possible to successfully remove an abnormal gland in 21 patients, including 12 with a negative or discordant US/Tc-99m-sestaMIBI scintigraphy result, with a global cure rate of 73%. CONCLUSION: FCH-PET/CT is a promising tool in the challenging population of reoperative patients with pHPT. Parathyroid 4D-CT appears as a confirmatory imaging modality.
BACKGROUND: To evaluate FCH-PET/CT and parathyroid 4D-CT so as to guide surgery in patients with primary hyperparathyroidism (pHPT) and prior neck surgery. METHODS: Medical records of all patients referred for a FCH-PET/CT in our institution were systematically reviewed. Only patients with pHPT, a history of neck surgery (for pHPT or another reason) and an indication of reoperation were included. All patients had parathyroid ultrasound (US) and Tc-99m-sestaMIBI scintigraphy, and furthermore, some patients had 4D-CT. Gold standard was defined by pathological findings and/or US-guided fine-needle aspiration with PTH level measurement in the washing liquid. RESULTS: Twenty-nine patients were included in this retrospective study. FCH-PET/CT identified 34 abnormal foci including 19 ectopic localizations. 4D-CT, performed in 20 patients, detected 11 abnormal glands at first reading and 6 more under FCH-PET/CT guidance. US and Tc-99m-sestaMIBI found concordant foci in 8/29 patients. Gold standard was obtained for 32 abnormal FCH-PET/CT foci in 27 patients. On a per-lesion analysis, sensitivity, specificity, positive and negative predictive values were, respectively, 96%, 13%, 77% and 50% for FCH-PET/CT, 75%, 40%, 80% and 33% for 4D-CT. On a per-patient analysis, sensitivity was 85% for FCH-PET/CT and 63% for 4D-CT. FCH-PET/CT results made it possible to successfully remove an abnormal gland in 21 patients, including 12 with a negative or discordant US/Tc-99m-sestaMIBI scintigraphy result, with a global cure rate of 73%. CONCLUSION:FCH-PET/CT is a promising tool in the challenging population of reoperative patients with pHPT. Parathyroid 4D-CT appears as a confirmatory imaging modality.
Authors: Wouter P Kluijfhout; Wessel M C M Vorselaars; Menno R Vriens; Inne H M Borel Rinkes; Gerlof D Valk; Bart de Keizer Journal: Eur J Radiol Date: 2015-05-21 Impact factor: 3.528
Authors: Daniël H van Raalte; Mariska C Vlot; Anthonie Zwijnenburg; Reinier W ten Kate Journal: Clin Endocrinol (Oxf) Date: 2015-01-15 Impact factor: 3.478
Authors: Brendan C Stack; David N Bimston; Donald L Bodenner; Elise M Brett; Henning Dralle; Lisa A Orloff; Johanna Pallota; Samuel K Snyder; Richard J Wong; Gregory W Randolph Journal: Endocr Pract Date: 2015-06 Impact factor: 3.443
Authors: Andrew M Hinson; David R Lee; Bradley A Hobbs; Ryan T Fitzgerald; Donald L Bodenner; Brendan C Stack Journal: Otolaryngol Head Neck Surg Date: 2015-08-06 Impact factor: 3.497
Authors: Diego Alfonso López-Mora; Marina Sizova; Montserrat Estorch; Albert Flotats; Valle Camacho; Alejandro Fernández; Safae Abouzian; Francisco Fuentes-Ocampo; José Ignacio Pérez Garcia; Ana Isabel Chico Ballesteros; Joan Duch; Anna Domènech; Antonio Moral Duarte; Ignasi Carrió Journal: Eur J Nucl Med Mol Imaging Date: 2020-01-09 Impact factor: 9.236
Authors: Arnoldo Piccardo; Gianluca Bottoni; Luis Alejandro Boccalatte; Chiara Camponovo; Martina Musumeci; Lorenzo Bacigalupo; Carlos Collaud; Martina Ugolini; Francesco Fiz; Pierpaolo Trimboli Journal: Endocrine Date: 2021-06-25 Impact factor: 3.633